Eton Pharmaceuticals CEO Sean Brynjelsen sells $6.08m in stock

Eton Pharmaceuticals (ETON) reported Q2 2026 revenue of $37.6M, up 99% YoY, driven by HEMANGEOL relaunch and pediatric endocrinology growth. FY 2026 revenue guidance raised to over $145M. Adjusted EBITDA was $16.2M (43% margin). ASN-001 licensing and study costs total $7M. Non-GAAP net income was $14.3M ($0.43/diluted share).

Analysts upgraded Eton Pharmaceuticals' (ETON) 2026 revenue forecast to $150M (up 42% YoY) and EPS to $1.09 (up 145%). The price target increased 30% to $71.00. The stock gained 51% in the last 7 days. Analysts expect growth to accelerate, outpacing industry averages.

Eton Pharmaceuticals (ETON) reported Q2 2026 revenue of $37.6M, up 99% year over year, driven by HEMANGEOL sales. Net income was $11.6M, or $0.35/share, versus a net loss in Q2 2025. The company raised 2026 revenue guidance to over $145M and expects adjusted EBITDA margin of at least 35%.

Eton Pharmaceuticals (ETON) reported Q2 2026 revenue of $37.59M versus $18.93M a year earlier, and net income of $11.58M versus a $2.59M loss. The company raised full-year 2026 revenue guidance to at least $145M. Eton also licensed ASN-001 and named Danka Radosavljevic COO.

Eton Pharmaceuticals (NASDAQ: ETON) shares rose sharply after its Q2 results and guidance. The company reported Q2 revenue of $37.6M versus about $27M expected and non-GAAP EPS of $0.43 versus $0.19 consensus. Management raised 2026 revenue guidance to over $145M and adjusted EBITDA margin to at least 35%.

Simply Wall St reports Eton Pharmaceuticals (ETON) shares rose 44.3% to $58.86 after Q2 results showed a profit inflection. Q2 revenue was $37.6m, net income $11.6m, and basic EPS $0.42, versus prior-year loss. Management lifted 2026 revenue guidance to over $145m from over $120m and kept a long-term EBITDA margin target above 50%.